CSIMarket
 
Jasper Therapeutics Inc   (JSPR)
 

News




Jasper Therapeutics Advancing Briquilimab in the Treatment of Urticaria: An Analysis of Recent Developments

Positive Results Show Briquilimab*s Potential as a Novel Therapy for Fanconi Anemia and Mast Cell Driven Diseases

Jasper Therapeutics Presents Promising Preclinical Data on Briquilimab, Targeting Mast Cell-Driven Diseases, at AAAAI Annual Meeting

Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock, Aims to Enhance Treatment Approaches for Mast-Cell Driven Diseases

Promising Preclinical Data for Briquilimab Presented at AAAAI 2024 Annual Meeting: A Potential Breakthrough in Treating Mast Cell Driven Diseases and Myelodysplastic Syndromes

Jasper Therapeutics Induces Employee Engagement with Stock Option Grants

Jasper Therapeutics: Revolutionary Antibody Therapy and Stock Split Point to Promising Future

Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria

JSPR experiences disturbing decline in corporate performance during latest fiscal period

Jasper Therapeutics Inc Reports Larger Shortfall in Q2 2023 Despite Positive Market Performance

Jasper Therapeutics Inc Struggles with Financial Turmoil, Reporting a Cumulative Net Loss of $50 Million and a Negative ROE of -74.37% During the Most Recent Fiscal Period

The company published Revenue of $0.507 millions, in the October to December 31 2022

The company declared operating loss in the third quarter of 2022

reported Revenue of $0.625 million, in the Jun 30 2022 report

Top-line was $4.593 million at the company in most recent fiscal period

Jasper Therapeutics Inc has Turned into Profitability at the Jasper Therapeutics Inc in fourth quarter of 2021









Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com